Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.
Also called NCT07704190
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Registry
-
NCT07704190
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07704190. Randomized; no masking; primary purpose treatment. Start 2026-07-15 (anticipated); primary completion 2028-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease
- Condition
- Cardiorenal Metabolic Syndrome
- Condition
- Atherosclerotic Cardiovascular Disease
- Condition
- Chronic Kidney Disease
- Condition
- Coronary Artery Disease
- Condition
- Hypertension
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Peripheral Arterial Disease
- Condition
- Carotid Artery Stenosis
- Intervention (Biological)
- Secukinumab (75 mg)
- Intervention (Other)
- Standard Medical Therapy
- Lead sponsor
- Peking University Third Hospital
Record details
- Record id
cardio:ct-nct07704190- Content hash
bc400021cf3d1bfce11cfdf665a75348e27faad289850f447cb49cba17a0c324